To the Editor:Upadacitinib,an oral janus kinase(JAK)inhibitor,exhibits a higher inhibitory potency for JAK1 compared to JAK2,JAK3,or tyrosine kinase 2,making it a promising candidate for the treatment of atopic dermat...To the Editor:Upadacitinib,an oral janus kinase(JAK)inhibitor,exhibits a higher inhibitory potency for JAK1 compared to JAK2,JAK3,or tyrosine kinase 2,making it a promising candidate for the treatment of atopic dermatitis(AD).Global trials Measure Up 1,Measure Up 2,and AD Up have demonstrated efficacy and safety data for moderate-to-severe AD,both as monotherapy and in combination with topical corticosteroids(TCS).[1,2]The updated 52-week results preliminarily reported sustained clinical benefits over 52 weeks,[3,4]but data on long-term outcomes in Chinese patients remain limited.Ethnic differences in AD pathophysiology,including variations in immune signatures,underscore the need for region-specific evidence.[5]This post hoc analysis of Measure Up 1 and AD Up trials evaluates the 140-week efficacy and safety of upadacitinib in Chinese patients.展开更多
文摘To the Editor:Upadacitinib,an oral janus kinase(JAK)inhibitor,exhibits a higher inhibitory potency for JAK1 compared to JAK2,JAK3,or tyrosine kinase 2,making it a promising candidate for the treatment of atopic dermatitis(AD).Global trials Measure Up 1,Measure Up 2,and AD Up have demonstrated efficacy and safety data for moderate-to-severe AD,both as monotherapy and in combination with topical corticosteroids(TCS).[1,2]The updated 52-week results preliminarily reported sustained clinical benefits over 52 weeks,[3,4]but data on long-term outcomes in Chinese patients remain limited.Ethnic differences in AD pathophysiology,including variations in immune signatures,underscore the need for region-specific evidence.[5]This post hoc analysis of Measure Up 1 and AD Up trials evaluates the 140-week efficacy and safety of upadacitinib in Chinese patients.
